Vitamin D may reset immune response in people with IBD after 12 weeks

A small study of 48 adults with ulcerative colitis or Crohn's disease found that 12 weeks of weekly vitamin D supplementation was associated with increased IgA, reduced IgG, changes in gut microbes and lower disease activity scores. The trial was small, nonrandomized and did not include a placebo control.

A recent, small study published in Cell Reports Medicine examined the effects of vitamin D supplementation in adults with inflammatory bowel disease (IBD). The trial enrolled 48 people with either ulcerative colitis or Crohn's disease who had low serum vitamin D and gave weekly vitamin D doses for 12 weeks, with blood and stool samples collected at baseline and at the end of the study. Researchers analyzed immune markers, immunoglobulins, microbial composition and clinical measures such as disease activity and stool inflammation markers. External experts and the study team described the results as exploratory and noted limitations in study design and duration. Key findings: - The study included 48 adults with ulcerative colitis or Crohn's disease and low vitamin D who received weekly vitamin D for 12 weeks. - After 12 weeks, researchers reported higher levels of IgA and lower levels of IgG, shifts in intestinal microbial composition, and reductions in disease activity scores and stool-based inflammation markers. - Investigators described the immune changes as a shift toward greater immune tolerance of gut bacteria rather than only reduced inflammation. - The trial was not randomized and had no placebo control; clinical endpoints were described as exploratory and longer-term effects were not assessed. - Experts and the authors noted unanswered questions including how vitamin D receptor activity, precise dosing, and interactions with other treatments relate to the observed changes. Summary: The study suggests that short-term vitamin D supplementation was associated with immune and microbiome changes alongside lower symptom scores in this small IBD group, but it does not establish definitive clinical benefit. Larger, randomized and longer-term studies are needed to confirm these findings and to clarify mechanisms, appropriate dosing and how effects might interact with other therapies; the next steps are therefore undetermined at this time.